메뉴 건너뛰기




Volumn 6, Issue 7, 2010, Pages 863-871

Telmisartan: A review of its pharmacodynamic and pharmacokinetic properties

Author keywords

ABC transporters; Angiotensin receptor blockers; Cardiovascular prevention; Hypertension; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; ENALAPRIL; LISINOPRIL; NISOLDIPINE; PLACEBO; RAMIPRIL; TELMISARTAN;

EID: 77953919950     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.494597     Document Type: Review
Times cited : (56)

References (75)
  • 1
    • 72949132104 scopus 로고
    • Factors of risk in the development of coronary heart disease - Six year follow-up experience. The Framingham Study
    • Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50
    • (1961) Ann Intern Med , vol.55 , pp. 33-50
    • Kannel, W.B.1    Dawber, T.R.2    Kagan, A.3
  • 2
    • 0025818120 scopus 로고
    • Chronic renal failure: Pathophysiology
    • Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991;338:419-423
    • (1991) Lancet , vol.338 , pp. 419-423
    • Jacobson, H.R.1
  • 3
    • 0015333482 scopus 로고
    • Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
    • Laragh JH, Baer L, Brunner HR, et al. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972;52:633-652
    • (1972) Am J Med , vol.52 , pp. 633-652
    • Laragh, J.H.1    Baer, L.2    Brunner, H.R.3
  • 4
    • 0017045374 scopus 로고
    • Role of hypertension in atherosclerosis and cardiovascular disease
    • Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol 1976;38:786-800
    • (1976) Am J Cardiol , vol.38 , pp. 786-800
    • Hollander, W.1
  • 5
    • 33845210475 scopus 로고    scopus 로고
    • Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
    • Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006;103:17985-17990
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 17985-17990
    • Crowley, S.D.1    Gurley, S.B.2    Herrera, M.J.3
  • 7
    • 42049103473 scopus 로고    scopus 로고
    • Pleiotropic effects of telmisartan: Still more to come?
    • Benndorf RA, Boger RH. Pleiotropic effects of telmisartan: still more to come? J Hypertens 2008;26:854-856
    • (2008) J Hypertens , vol.26 , pp. 854-856
    • Benndorf, R.A.1    Boger, R.H.2
  • 8
    • 31444437343 scopus 로고    scopus 로고
    • Telmisartan: A review of its use in the management of hypertension
    • Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66(1):51-83
    • (2006) Drugs , vol.66 , Issue.1 , pp. 51-83
    • Battershill, A.J.1    Scott, L.J.2
  • 9
    • 19944372857 scopus 로고    scopus 로고
    • Telmisartan (Micardis) 60th edition. Montvale, NJ, Medical Economics
    • Telmisartan (Micardis-). Physicians' desk reference. 60th edition. Montvale, NJ, Medical Economics; 2005. p. 997-999
    • (2005) Physicians' Desk Reference , pp. 997-999
  • 10
    • 77953920477 scopus 로고    scopus 로고
    • (Dok.-Ref.: EMA/829297/2009; EMEA/H/C/210). Available from [Last accessed 31 March 2010]
    • EMEA document regarding the approval of telmisartan by the European commission. (Dok.-Ref.: EMA/829297/ 2009; EMEA/H/C/210). Available from: http://www.ema.europa.eu/humandocs/ PDFs/EPAR/Pritor/198798de1.pdf. [Last accessed 31 March 2010]
    • EMEA Document Regarding the Approval of Telmisartan by the European Commission
  • 11
    • 77953922394 scopus 로고    scopus 로고
    • from July 28, Available from [Last accessed 31 March 2010]
    • Micardis Briefing document for the Cardiovascular and Renal Drugs Advisory Committee (FDA) from July 28, 2009. Available from: http:// www.fda.gov/downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisory Committee/UCM173529.pdf. [Last accessed 31 March 2010]
    • (2009) Micardis Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (FDA)
  • 12
    • 0027218706 scopus 로고
    • Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
    • Wienen W, Hauel N, Van Meel JC, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-252
    • (1993) Br J Pharmacol , vol.110 , pp. 245-252
    • Wienen, W.1    Hauel, N.2    Van Meel, J.C.3
  • 13
    • 1542547460 scopus 로고    scopus 로고
    • Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity
    • Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002
    • (2004) Hypertension , vol.43 , pp. 993-1002
    • Benson, S.C.1    Pershadsingh, H.A.2    Ho, C.I.3
  • 14
    • 2442451618 scopus 로고    scopus 로고
    • Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    • Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-2057
    • (2004) Circulation , vol.109 , pp. 2054-2057
    • Schupp, M.1    Janke, J.2    Clasen, R.3
  • 15
    • 33747131444 scopus 로고    scopus 로고
    • Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
    • Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006;55:1159-1164
    • (2006) Metabolism , vol.55 , pp. 1159-1164
    • Benndorf, R.A.1    Rudolph, T.2    Appel, D.3
  • 16
    • 33847125757 scopus 로고    scopus 로고
    • Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension
    • Bajcetic M, Benndorf RA, Appel D, et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 2007;47:295-304
    • (2007) J Clin Pharmacol , vol.47 , pp. 295-304
    • Bajcetic, M.1    Benndorf, R.A.2    Appel, D.3
  • 17
    • 20344400660 scopus 로고    scopus 로고
    • Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue
    • Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005;96:1042-1052
    • (2005) Circ Res , vol.96 , pp. 1042-1052
    • Yu, Y.H.1    Ginsberg, H.N.2
  • 18
    • 48449106424 scopus 로고    scopus 로고
    • Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan
    • Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57:1405-1413
    • (2008) Diabetes , vol.57 , pp. 1405-1413
    • Clemenz, M.1    Frost, N.2    Schupp, M.3
  • 19
    • 67449108376 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease
    • Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009;205:1-8
    • (2009) Atherosclerosis , vol.205 , pp. 1-8
    • Fruchart, J.C.1
  • 20
    • 0035146287 scopus 로고    scopus 로고
    • Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes
    • Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001;24:392-397
    • (2001) Diabetes Care , vol.24 , pp. 392-397
    • Hsueh, W.A.1    Jackson, S.2    Law, R.E.3
  • 21
    • 40949119482 scopus 로고    scopus 로고
    • Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
    • Cianchetti S, Del Fiorentino A, Colognato R, et al. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008;198:22-28
    • (2008) Atherosclerosis , vol.198 , pp. 22-28
    • Cianchetti, S.1    Del Fiorentino, A.2    Colognato, R.3
  • 22
    • 42049108222 scopus 로고    scopus 로고
    • Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same?
    • Benson SC, Iguchi R, Ho CI, et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 2008;26:973-980
    • (2008) J Hypertens , vol.26 , pp. 973-980
    • Benson, S.C.1    Iguchi, R.2    Ho, C.I.3
  • 23
    • 37449001505 scopus 로고    scopus 로고
    • Telmisartan improves endothelial function in patients with essential hypertension
    • Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-371
    • (2007) J Cardiovasc Pharmacol , vol.50 , pp. 367-371
    • Benndorf, R.A.1    Appel, D.2    Maas, R.3
  • 24
    • 0033740069 scopus 로고    scopus 로고
    • Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers
    • Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1312-1322
    • (2000) J Clin Pharmacol , vol.40 , pp. 1312-1322
    • Stangier, J.1    Schmid, J.2    Turck, D.3
  • 25
    • 0033840660 scopus 로고    scopus 로고
    • Pharmacokinetics of orally and intravenous administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
    • Stangier J, Su CA, Roth W, et al. Pharmacokinetics of orally and intravenous administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-172
    • (2000) J Int Med Res , vol.28 , pp. 149-172
    • Stangier, J.1    Su, C.A.2    Roth, W.3
  • 26
    • 33745253947 scopus 로고    scopus 로고
    • Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
    • Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006;34:1109-1115
    • (2006) Drug Metab Dispos , vol.34 , pp. 1109-1115
    • Ishiguro, N.1    Maeda, K.2    Kishimoto, W.3
  • 27
    • 41549098278 scopus 로고    scopus 로고
    • Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide
    • Ishiguro N, Maeda K, Saito A, et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008;36:796-805
    • (2008) Drug Metab Dispos , vol.36 , pp. 796-805
    • Ishiguro, N.1    Maeda, K.2    Saito, A.3
  • 28
    • 77953933130 scopus 로고    scopus 로고
    • Micardis full prescribing information of the EMEA. Available from [Last accessed 5 May 2010]
    • Micardis full prescribing information of the EMEA. Available from: http:// www.ema.europa.eu/humandocs/PDFs/ EPAR/Micardis/emea-combined-h209en. pdf. [Last accessed 5 May 2010]
  • 29
    • 77953946421 scopus 로고    scopus 로고
    • Available from[Last accessed 5 May 2010]
    • Micardis full prescribing information of the FDA. Available from: http:// www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020850s025lbl.pdf. [Last accessed 5 May 2010]
    • Micardis Full Prescribing Information of the FDA
  • 30
    • 0029128720 scopus 로고
    • Gender effects in pharmacokinetics and pharmacodynamics
    • Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239
    • (1995) Drugs , vol.50 , pp. 222-239
    • Harris, R.Z.1    Benet, L.Z.2    Schwartz, J.B.3
  • 31
    • 0033749163 scopus 로고    scopus 로고
    • Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: Comparison with healthy volunteers
    • Stangier J, Su Chung-An PF, Brickl R, et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40:1365-1372
    • (2000) J Clin Pharmacol , vol.40 , pp. 1365-1372
    • Stangier, J.1    Su Chung-An, P.F.2    Brickl, R.3
  • 32
    • 70349603042 scopus 로고    scopus 로고
    • Pharmacokinetics and dosage adjustment in patients with renal dysfunction
    • Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-773
    • (2009) Eur J Clin Pharmacol , vol.65 , pp. 757-773
    • Verbeeck, R.K.1    Musuamba, F.T.2
  • 33
    • 0033748477 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
    • Stangier J, Su Chung-An PF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharamcol 2000;40:1355-1364
    • (2000) J Clin Pharamcol , vol.40 , pp. 1355-1364
    • Stangier, J.1    Su Chung-An, P.F.2    Schondorfer, G.3
  • 34
    • 0043124614 scopus 로고    scopus 로고
    • Drug interactions with angiotensin receptor blockers: A comparison with other antihypertensives
    • Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003;26:707-720
    • (2003) Drug Saf , vol.26 , pp. 707-720
    • Unger, T.1    Kaschina, E.2
  • 35
    • 77951031222 scopus 로고    scopus 로고
    • Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters
    • Weiss J, Sauer A, Divac N, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-161
    • (2010) Biopharm Drug Dispos , vol.31 , pp. 150-161
    • Weiss, J.1    Sauer, A.2    Divac, N.3
  • 36
    • 0033731288 scopus 로고    scopus 로고
    • Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
    • Stangier J, Su C-APF. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1347-1354
    • (2000) J Clin Pharmacol , vol.40 , pp. 1347-1354
    • Stangier, J.1    C-Apf, S.2
  • 38
    • 42049107348 scopus 로고    scopus 로고
    • The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Yusuf S, Teo KK, Pogue J, et al. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3
  • 39
    • 0033732238 scopus 로고    scopus 로고
    • Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
    • Stangier J, Su C-APF, Hendriks MGC, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol 2000;40:1331-1337
    • (2000) J Clin Pharmacol , vol.40 , pp. 1331-1337
    • Stangier, J.1    C-Apf, S.2    Mgc, H.3
  • 40
    • 0033749283 scopus 로고    scopus 로고
    • Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers
    • Stangier J, Su C-APF, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1338-1346
    • (2000) J Clin Pharmacol , vol.40 , pp. 1338-1346
    • Stangier, J.1    C-Apf, S.2    Fraunhofer, A.3
  • 41
    • 0033747596 scopus 로고    scopus 로고
    • Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
    • Yong C-L, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000;40:1323-1330
    • (2000) J Clin Pharmacol , vol.40 , pp. 1323-1330
    • Yong, C.-L.1    Dias, V.C.2    Stangier, J.3
  • 42
    • 0033815393 scopus 로고    scopus 로고
    • Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan
    • Nishino A, Kato Y, Igarashi T, et al. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan. Drug Metab Dispos 2000;28:1146-1148
    • (2000) Drug Metab Dispos , vol.28 , pp. 1146-1148
    • Nishino, A.1    Kato, Y.2    Igarashi, T.3
  • 43
    • 57049170781 scopus 로고    scopus 로고
    • Telmisartan pharmacokinetics in Japanese renal transplant recipients
    • Miura M, Satoh S, Inoue K, et al. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta 2009;399:83-87
    • (2009) Clin Chim Acta , vol.399 , pp. 83-87
    • Miura, M.1    Satoh, S.2    Inoue, K.3
  • 44
    • 58149263115 scopus 로고    scopus 로고
    • No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects
    • Guo X, Chen XP, Cheng ZN, et al. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med 2009;47:38-43
    • (2009) Clin Chem Lab Med , vol.47 , pp. 38-43
    • Guo, X.1    Chen, X.P.2    Cheng, Z.N.3
  • 45
    • 33751525373 scopus 로고    scopus 로고
    • Rapid identification of P-glycoprotein substrates and inhibitors
    • Chang C, Bahadduri PM, Polli JE, et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006;34:1976-1984
    • (2006) Drug Metab Dispos , vol.34 , pp. 1976-1984
    • Chang, C.1    Bahadduri, P.M.2    Polli, J.E.3
  • 46
    • 58549088199 scopus 로고    scopus 로고
    • Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug
    • Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-181
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 173-181
    • Fenner, K.S.1    Troutman, M.D.2    Kempshall, S.3
  • 47
    • 77449143886 scopus 로고    scopus 로고
    • Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes
    • Kamiyama E, Nakai D, Mikkaichi T, et al. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52-58
    • (2010) Life Sci , vol.86 , pp. 52-58
    • Kamiyama, E.1    Nakai, D.2    Mikkaichi, T.3
  • 48
    • 0033748479 scopus 로고    scopus 로고
    • The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
    • Stangier J, Su C-APF, Hendriks MGC, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000;40:1373-1379
    • (2000) J Clin Pharmacol , vol.40 , pp. 1373-1379
    • Stangier, J.1    C-Apf, S.2    Mgc, H.3
  • 49
    • 12344282783 scopus 로고    scopus 로고
    • Global burden of hypertension: Analysis of worldwide data
    • Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223
    • (2005) Lancet , vol.365 , pp. 217-223
    • Kearney, P.M.1    Whelton, M.2    Reynolds, K.3
  • 50
    • 0347423198 scopus 로고    scopus 로고
    • Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. National Heart Lung and Blood Institute; National High Blood Pressure Education Program Coordinating CommitteeSeventh report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure
    • Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating CommitteeSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 51
    • 0041589771 scopus 로고    scopus 로고
    • Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - A randomised ABPM study
    • Neutel JM, Kolloch RE, Plouin PF, et al. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - a randomised ABPM study. J Hum Hypertens 2003;17:569-575
    • (2003) J Hum Hypertens , vol.17 , pp. 569-575
    • Neutel, J.M.1    Kolloch, R.E.2    Plouin, P.F.3
  • 52
    • 10344250394 scopus 로고    scopus 로고
    • Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: A multicentre, randomised, double-blind study
    • Zhu JR, Bai J, Cai NS, et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 2004;145:46-49
    • (2004) Int J Clin Pract Suppl , vol.145 , pp. 46-49
    • Zhu, J.R.1    Bai, J.2    Cai, N.S.3
  • 53
    • 0033784560 scopus 로고    scopus 로고
    • A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring
    • Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-1132
    • (2000) Can J Cardiol , vol.16 , pp. 1123-1132
    • Littlejohn, T.1    Mroczek, W.2    Marbury, T.3
  • 54
    • 1842562367 scopus 로고    scopus 로고
    • Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period
    • White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-353
    • (2004) Am J Hypertens , vol.17 , pp. 347-353
    • White, W.B.1    Lacourciere, Y.2    Davidai, G.3
  • 55
    • 44949104716 scopus 로고    scopus 로고
    • Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
    • Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-1225
    • (2008) Drugs , vol.68 , pp. 1207-1225
    • Smith, D.H.1
  • 56
    • 0141753977 scopus 로고    scopus 로고
    • Blood pressure- and pulse pressure-lowering effects, trough: Peak ratio and smoothness index of telmisartan compared with lisinopril
    • Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure- and pulse pressure-lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42:491-496
    • (2003) J Cardiovasc Pharmacol , vol.42 , pp. 491-496
    • Stergiou, G.S.1    Efstathiou, S.P.2    Roussias, L.G.3    Mountokalakis, T.D.4
  • 57
    • 0036810631 scopus 로고    scopus 로고
    • Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: A review of clinical studies of telmisartan and enalapril
    • Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002;24:1484-1501
    • (2002) Clin Ther , vol.24 , pp. 1484-1501
    • Smith, D.H.1
  • 58
    • 10344251467 scopus 로고    scopus 로고
    • Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension
    • Alcocer L, Fernandez-Bonetti P, Campos E, et al. Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:35-39
    • (2004) Int J Clin Pract Suppl , vol.145 , pp. 35-39
    • Alcocer, L.1    Fernandez-Bonetti, P.2    Campos, E.3
  • 59
    • 0032423365 scopus 로고    scopus 로고
    • A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
    • Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998;3:295-302
    • (1998) Blood Press Monit , vol.3 , pp. 295-302
    • Lacourciere, Y.1    Lenis, J.2    Orchard, R.3
  • 60
    • 0035153980 scopus 로고    scopus 로고
    • Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study
    • Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group
    • Freytag F, Schelling A, Meinicke T, et al. Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001;23:108-123
    • (2001) Clin Ther , vol.23 , pp. 108-123
    • Freytag, F.1    Schelling, A.2    Meinicke, T.3
  • 61
    • 0347765700 scopus 로고    scopus 로고
    • The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy
    • Gil-Extremera B, Ma PT, Yulde J, et al. The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. Int J Clin Pract 2003;57:861-866
    • (2003) Int J Clin Pract , vol.57 , pp. 861-866
    • Gil-Extremera, B.1    Ma, P.T.2    Yulde, J.3
  • 62
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3
  • 63
    • 0042330455 scopus 로고    scopus 로고
    • EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
    • (2003) Lancet , vol.362 , pp. 782-788
    • Fox, K.M.1
  • 64
    • 19644400972 scopus 로고    scopus 로고
    • PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease
    • Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068
    • (2004) N Engl J Med , vol.351 , pp. 2058-2068
    • Braunwald, E.1    Domanski, M.J.2    Fowler, S.E.3
  • 65
    • 0030902115 scopus 로고    scopus 로고
    • Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
    • Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752
    • (1997) Lancet , vol.349 , pp. 747-752
    • Pitt, B.1    Segal, R.2    Martinez, F.A.3
  • 66
    • 0041408235 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-added trial
    • DOI 10.1016/S0140-6736(03)14283-3
    • McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
    • (2003) Lancet , vol.362 , Issue.9386 , pp. 767-771
    • McMurray, J.J.V.1    Ostergren, J.2    Swedberg, K.3    Granger, C.B.4    Held, P.5    Michelson, E.L.6    Olofsson, B.7    Yusuf, S.8    Pfeffer, M.A.9
  • 67
    • 3142740224 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials
    • ONTARGET/TRANSCEND Investigators
    • Teo K, Yusuf S, Sleight P, et al. ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004;148:52-61
    • (2004) Am Heart J , vol.148 , pp. 52-61
    • Teo, K.1    Yusuf, S.2    Sleight, P.3
  • 68
    • 53049109468 scopus 로고    scopus 로고
    • Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial
    • Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183
    • (2008) Lancet , vol.372 , pp. 1174-1183
    • Yusuf, S.1    Teo, K.2    Anderson, C.3
  • 69
    • 51449085994 scopus 로고    scopus 로고
    • Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled study
    • Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group
    • Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-884
    • (2008) Lancet Neurol , vol.7 , pp. 875-884
    • Diener, H.C.1    Sacco, R.L.2    Yusuf, S.3
  • 70
    • 0034888870 scopus 로고    scopus 로고
    • Discontinuation of antihypertensive drugs due to adverse events: A systematic review and meta-analysis
    • Ross SD, Akhras KS, Zhang S, et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001;21:940-953
    • (2001) Pharmacotherapy , vol.21 , pp. 940-953
    • Ross, S.D.1    Akhras, K.S.2    Zhang, S.3
  • 71
    • 1942467808 scopus 로고    scopus 로고
    • Safety of telmisartan in patients with arterial hypertension: An open-label observational study
    • Michel MC, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27:335-344
    • (2004) Drug Saf , vol.27 , pp. 335-344
    • Michel, M.C.1    Bohner, H.2    Koster, J.3
  • 72
    • 0032896412 scopus 로고    scopus 로고
    • Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension
    • Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999;6:161-166
    • (1999) Am J Ther , vol.6 , pp. 161-166
    • Neutel, J.M.1    Frishman, W.H.2    Oparil, S.3
  • 73
    • 29244484441 scopus 로고    scopus 로고
    • The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)
    • PRISMA I Study Group
    • Williams B, Gosse P, Lowe L, et al. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200
    • (2006) J Hypertens , vol.24 , pp. 193-200
    • Williams, B.1    Gosse, P.2    Lowe, L.3
  • 74
    • 0035528585 scopus 로고    scopus 로고
    • Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension
    • French Collaborative Telmisartan Study Group
    • Hannedouche T, Chanard J, Baumelou B. French Collaborative Telmisartan Study Group. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001;2:246-254
    • (2001) J Renin Angiotensin Aldosterone Syst , vol.2 , pp. 246-254
    • Hannedouche, T.1    Chanard, J.2    Baumelou, B.3
  • 75
    • 25844453959 scopus 로고    scopus 로고
    • Ventricular and vascular remodelling: Effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients
    • Petrovic J, Petrovic D, Vukovic N, et al. Ventricular and vascular remodelling: effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33:39-49A
    • (2005) J Int Med Res , vol.33
    • Petrovic, J.1    Petrovic, D.2    Vukovic, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.